75 related articles for article (PubMed ID: 11739135)
1. The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program.
van den Boom G; Rutten-van Mölken MP; Molema J; Tirimanna PR; van Weel C; van Schayck CP
Am J Respir Crit Care Med; 2001 Dec; 164(11):2057-66. PubMed ID: 11739135
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW
Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652
[TBL] [Abstract][Full Text] [Related]
3. Early intervention with inhaled corticosteroids in subjects with rapid decline in lung function and signs of bronchial hyperresponsiveness: results from the DIMCA programme.
den Otter JJ; van Schayck CP; Folgering HT; van den Boom G; Akkermans RP; van Weel C
Eur J Gen Pract; 2007; 13(2):89-91. PubMed ID: 17534745
[TBL] [Abstract][Full Text] [Related]
4. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data.
Briggs AH; Lozano-Ortega G; Spencer S; Bale G; Spencer MD; Burge PS
Value Health; 2006; 9(4):227-35. PubMed ID: 16903992
[TBL] [Abstract][Full Text] [Related]
5. Controlled trial of inhaled fluticasone propionate in moderate to severe COPD.
Thompson WH; Carvalho P; Souza JP; Charan NB
Lung; 2002; 180(4):191-201. PubMed ID: 12391509
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of inhaled steroids in undiagnosed subjects at high risk for COPD: results of the detection, intervention, and monitoring of COPD and asthma program.
Albers M; Schermer T; van den Boom G; Akkermans R; van Schayck C; van Herwaarden C; van Weel C
Chest; 2004 Dec; 126(6):1815-24. PubMed ID: 15596679
[TBL] [Abstract][Full Text] [Related]
7. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.
Barnes NC; Qiu YS; Pavord ID; Parker D; Davis PA; Zhu J; Johnson M; Thomson NC; Jeffery PK;
Am J Respir Crit Care Med; 2006 Apr; 173(7):736-43. PubMed ID: 16424444
[TBL] [Abstract][Full Text] [Related]
8. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial.
Ayres JG; Price MJ; Efthimiou J
Respir Med; 2003 Mar; 97(3):212-20. PubMed ID: 12645827
[TBL] [Abstract][Full Text] [Related]
10. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
[TBL] [Abstract][Full Text] [Related]
11. Development of an economic model to assess the cost effectiveness of asthma management strategies.
Price MJ; Briggs AH
Pharmacoeconomics; 2002; 20(3):183-94. PubMed ID: 11929348
[TBL] [Abstract][Full Text] [Related]
12. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study.
Hattotuwa KL; Gizycki MJ; Ansari TW; Jeffery PK; Barnes NC
Am J Respir Crit Care Med; 2002 Jun; 165(12):1592-6. PubMed ID: 12070058
[TBL] [Abstract][Full Text] [Related]
13. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
[TBL] [Abstract][Full Text] [Related]
14. Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: a double-blind, placebo-controlled study.
Noonan MJ; Chervinsky P; Wolfe J; Liddle R; Kellerman DJ; Crescenzi KL
J Asthma; 1998; 35(2):153-64. PubMed ID: 9576141
[TBL] [Abstract][Full Text] [Related]
15. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
[TBL] [Abstract][Full Text] [Related]
16. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
17. Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related.
Reid DW; Wen Y; Johns DP; Williams TJ; Ward C; Walters EH
Respirology; 2008 Nov; 13(6):799-809. PubMed ID: 18811878
[TBL] [Abstract][Full Text] [Related]
18. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
Oba Y
Am J Manag Care; 2009 Apr; 15(4):226-32. PubMed ID: 19355795
[TBL] [Abstract][Full Text] [Related]
20. Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma.
Galant SP; van Bavel J; Finn A; Gross G; Pleskow W; Brown A; Hamedani AG; Harding SM
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):273-80. PubMed ID: 10094218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
